Health Care & Life Sciences » Pharmaceuticals | Roopa Industries Ltd.

Roopa Industries Ltd. | Balance Sheet

Fiscal year is April-March. All values INR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
5,408.70
5,556.90
6,695.70
7,293.50
7,091.10
5,975
Total Accounts Receivable
73,900.50
69,305.80
56,536.20
105,940.40
121,149.90
129,014.60
Inventories
55,963.70
55,154.30
82,742.00
49,538.40
80,223.00
124,282.70
Other Current Assets
115.00
4,907.20
12,868.20
6,807.00
6,456.00
4,663.80
Total Current Assets
135,388.00
134,924.10
158,842.10
169,579.30
214,919.90
263,936.10
Net Property, Plant & Equipment
84,696.90
81,548.30
76,397.10
69,380.90
68,808.50
88,063.40
Total Investments and Advances
436.90
436.90
436.90
436.90
436.90
232.10
Other Assets
12,975.50
21,700.50
19,535.40
13,237.90
2,668.30
-
Total Assets
235,013.80
240,159.70
256,798.20
252,700.10
286,833.70
354,900
ST Debt & Current Portion LT Debt
39,743.20
52,028.40
49,697.10
35,164.10
42,419.60
Accounts Payable
55,462.00
64,109.10
74,346.40
66,115.50
62,107.60
Income Tax Payable
517.40
-
-
-
-
Other Current Liabilities
447.20
1,364.90
1,082.80
3,342.70
9,202.60
Total Current Liabilities
96,169.70
117,502.30
125,126.30
104,622.30
113,729.80
Long-Term Debt
23,733.30
26,870.60
33,958.70
49,031.20
70,327.10
Provision for Risks & Charges
2,167.90
2,275.90
2,395.10
2,605.80
2,504.80
Deferred Taxes
6,454.40
7,057.60
7,215.70
8,145.20
8,374.50
Total Liabilities
130,041.90
155,256.20
170,282.50
164,469.70
194,936.20
Common Equity (Total)
104,971.90
84,903.40
86,515.70
88,230.40
91,897.50
Total Shareholders' Equity
104,971.90
84,903.40
86,515.70
88,230.40
91,897.50
Total Equity
104,971.90
84,903.40
86,515.70
88,230.40
91,897.50
Liabilities & Shareholders' Equity
235,013.80
240,159.70
256,798.20
252,700.10
286,833.70

About Roopa Industries

View Profile
Address
6-2-1012, 3rd floor, TGV Mansion
Hyderabad TS 500004
India
Employees -
Website http://www.roopaindustries.com
Updated 07/08/2019
Roopa Industries Ltd. manufactures pharmaceutical products. It operates under the Manufacturing and Marketing of bulk drugs and intermediaries segment. Its products include triphenyl phosphine, glucosamine, bromine and its derivatives, esomeprazole magnesium trihydrate, and tamsulosin.